Progress of Auto-HSCT for Treatment of DLBCL--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1841-1846, 2018.
Article
em Zh
| WPRIM
| ID: wpr-774375
Biblioteca responsável:
WPRO
ABSTRACT
Diffuse large B cell lymphoma(DLBCL)is the most common non-Hodgkin's lymphoma in adults,accounting for 30%-40% of non-Hodgkin's lymphoma in adults. The treatments of this lymphoma mainly include chemotherapy,radiotherapy and autologous hematopoietic stem cell transplantation. A large amount of studies show that autologous hematopoietic stem cell transplantation considered as the main treatmant approach can be used for primary high-risk young and relapsed or refractory DLBCL patients. Many scholars have evaluated the effectiveness of autologous hematopoietic stem cell transplantation for primarily high-risk young and relapsed or refractory DLBCL patients,and tried to improve the effectiveness of transplantation that showed some advantagcs for DLBCL patients.
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Terapêutica
/
Transplante Autólogo
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Linfoma Difuso de Grandes Células B
/
Resultado do Tratamento
/
Transplante de Células-Tronco Hematopoéticas
/
Condicionamento Pré-Transplante
Limite:
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Ano de publicação:
2018
Tipo de documento:
Article